Alyeska Investment Group, L.P. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
Alyeska Investment Group, L.P. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$6,860,253
+185.1%
131,700
+246.6%
0.05%
+161.1%
Q2 2023$2,406,160
-11.1%
38,000
-24.0%
0.02%
-25.0%
Q1 2023$2,707,500
-61.0%
50,000
-77.1%
0.02%
-75.5%
Q4 2020$6,947,000
-51.3%
218,473
-60.7%
0.10%
-54.8%
Q3 2020$14,275,000
+107.2%
556,312
+107.3%
0.22%
+108.7%
Q2 2020$6,890,000
-6.1%
268,400
-43.8%
0.10%
-28.8%
Q1 2020$7,338,000
-15.3%
477,426
-13.0%
0.15%
+124.6%
Q3 2017$8,663,000
+332.7%
548,955
+997.9%
0.06%
+182.6%
Q3 2015$2,002,000
+150.2%
50,000
+99.8%
0.02%
+360.0%
Q2 2015$800,000
+77.0%
25,030
+32.4%
0.01%
-16.7%
Q1 2015$452,000
-55.7%
18,908
-67.3%
0.01%
-64.7%
Q4 2014$1,021,000
+24.1%
57,853
-3.6%
0.02%0.0%
Q3 2014$823,000
-61.1%
59,995
-52.2%
0.02%
-63.8%
Q2 2014$2,116,000
-40.2%
125,493
-35.5%
0.05%
-51.5%
Q1 2014$3,537,000194,5630.10%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders